Clinical Use of Neuronal Growth Factors in Neurodevelopmental Disorders

Yıl 2019, Cilt: 28 Sayı: 2, 98 - 107, 30.06.2019

Miraç Barış Usta Murat Terzi Koray Karabekiroğlu Armağan Aral

Öz

Neurodevelopmental disorders are disorders that cause severe dysfunction. These disorders begin in early childhood and have many complex etiologies that are not yet enlightened today. There are hypotheses and some evidence that in neurodevelopmental disorders about abnormal growth factor expression during embryogenesis. Recent studies have been reported that neuronal growth factors may also related to clinical conditions in this disorders. Along with increased evidence, changes in neuronal growth factor levels indicate common pathophysiological mechanisms between Attention Deficit and Hyperactivity Disorder and Autism Spectrum Disorder. Therefore, the investigation of all these related pathways and growth factors will lead to possible clinical uses of these neuronal growth factors for Attention Deficit and Hyperactivity Disorder and Autism Spectrum Disorder.

Anahtar Kelimeler

attention deficit and hyperactivity disorder, autism spectrum disorder, neuronal growth factors, biomarker

Nörogelişimsel Bozukluklarda Nöronal Büyüme Faktörlerinin Klinik Kullanımı

Öz

Nörogelişimsel bozukluklar, ciddi işlev kaybına neden olan bozukluklardır. Bu bozukluklar erken çocuklukta başlar ve bir çoğu henüz aydınlatılmamış kompleks etiyolojilere sahiptirler. Bir çok nörogelişimsel hastalıkta, embriyogenez esnasında anormal büyüme faktörü ekspresyonu olduğuna dair hipotez ve kanıtlar bulunmaktadır. Son yıllarda nöronal büyüme faktörlerininin klinik durumlarlada ilişkili olabileceğine dair bulgular bildirilmiştir. Artan kanıtlar ile beraber, nöronal büyüme faktör düzeylerindeki değişimler Dikkat Eksikliği ve Hiperaktivite Bozukluğu ve Otizm Spektrum Bozukluğu arasındaki ortak patofizyolojik mekanizmaları işaret etmektedir. Bu nedenle tüm bu ilişkili yolakların ve büyüme faktörlerinin araştırılması Dikkat Eksikliği ve Hiperaktivite Bozukluğu ve Otizm Spektrum Bozukluğu için bu nöronal büyüme faktörlerin olası klinik kullanımları için yol gösterecektir.

Anahtar Kelimeler

dehb, biyolojik belirteç, nöronal büyüme faktörü, otizm spektrum bozukluğu

Kaynakça

• Bothwell M. Neuronal growth factors: Springer and Verlag; Berlin 2013.
• Ahmed F, Hristova K. Mechanism of TRK Receptor dimerization and activation. Biophys J. 2018;114:462.
• Discher DE, Mooney DJ, Zandstra PW. Growth factors, matrices, and forces combine and control stem cells. Science. 2009;324:1673-7.
• Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, Gomez-Plascencia J, Ramos-Zuniga R, Gonzalez-Perez O. Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. Cytokine Growth Factor Rev. 2016;32:85-96.
• Jones KR, Reichardt LF. Molecular cloning of a human gene that is a member of the nerve growth factor family. Proc Natl Acad Sci USA. 1990;87:8060-4.
• Zhang H, Ozbay F, Lappalainen J, Kranzler HR, van Dyck CH, Charney DS, et al. Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet. 2006;141:387-93.
• Bath KG, Lee FS. Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosc. 2006;6:79-85.
• Dincheva I, Lynch NB, Lee FS. The role of BDNF in the development of fear learning. Depress Anxiety. 2016;33:907-16.
• Wegiel J, Kuchna I, Nowicki K, Imaki H, Wegiel J, Marchi E, et al. The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol. 2010;119:755-70.
• Galvez-Contreras AY, Gonzalez-Castaneda RE, Luquin S, Gonzalez-Perez O. Role of fibroblast growth factor receptors in astrocytic stem cells. Curr Signal Transduct Ther. 2012;7:81-6.
• Azadi Sohi B. Cognitive task performances as biomarkers and candidate endophenotypes in childhood neurodevelopmental disorders: PhD thesis, King's College London (University of London); 2012.
• Kwon HJ, Ha M, Jin HJ, Hyun JK, Shim SH, Paik KC, et al. Association between BDNF gene polymorphisms and attention deficit hyperactivity disorder in Korean children. Genet Test Mol Biomarkers. 2015;19:366-71.
• Hill EL. Evaluating the theory of executive dysfunction in autism. Developmental Review. 2004;24:189-233.
• Nijmeijer JS, Minderaa RB, Buitelaar JK, Mulligan A, Hartman CA, Hoekstra PJ. Attention-deficit/hyperactivity disorder and social dysfunctioning. Clin Psychol Rev. 2008;28:692-708.
• Ellison PAT, Semrud-Clikeman M. Child neuropsychology: Assessment and interventions for neurodevelopmental disorders: Springer Science and Business Media; Newyork, NY; 2007.
• Sinzig J, Morsch D, Lehmkuhl G. Do hyperactivity, impulsivity and inattention have an impact on the ability of facial affect recognition in children with autism and ADHD? Eur Child Adolesc Psychiatry. 2008;17:63-72.
• Pasciuto E, Borrie S, Kanellopoulos A, Santos A, Cappuyns E, D’andrea L, et al. Autism spectrum disorders: translating human deficits into mouse behavior. Neurobiol Learn Mem. 2015;124:71-87.
• Mary A, Slama H, Mousty P, Massat I, Capiau T, Drabs V, et al. Executive and attentional contributions to Theory of Mind deficit in attention deficit/hyperactivity disorder (ADHD). Child Neuropsychol. 2016;22:345-65.
• Craig F, Margari F, Legrottaglie AR, Palumbi R, De Giambattista C, Margari L. A review of executive function deficits in autism spectrum disorder and attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2016;12:1191.
• Devine RT, Hughes C. Relations between false belief understanding and executive function in early childhood: A meta‐analysis. Child Dev. 2014; 85: 1777-94.
• Aspan N, Bozsik C, Gadoros J, Nagy P, Inantsy-Pap J, Vida P, et al. Emotion recognition pattern in adolescent boys with attention-deficit/hyperactivity disorder. BioMed Research International. 2014.
• Shuai L, Chan RC, Wang Y. Executive function profile of Chinese boys with attention-deficit hyperactivity disorder: different subtypes and comorbidity. Arch Clin Neuropsychol. 2011;26:120-32.
• Charman T, Carroll F, Sturge C. Theory of mind, executive function and social competence in boys with ADHD. Emotional and Behavioural Difficulties. 2001;6:31-49.
• Visser JC, Rommelse NN, Greven CU, Buitelaar JK. Autism spectrum disorder and attention-deficit/hyperactivity disorder in early childhood: a review of unique and shared characteristics and developmental antecedents. Neurosci Biobehav Rev. 2016;65:229-63.
• Zeni C, Tramontina S, Aguiar B, Salatino‐Oliveira A, Pheula G, Sharma A, et al. BDNF Val66Met polymorphism and peripheral protein levels in pediatric bipolar disorder and attention‐deficit/hyperactivity disorder. Acta Psychiatr Scand. 2016;134:268-74.
• Shim S-H, Hwangbo Y, Yoon H-J, Kwon Y-J, Lee H-Y, Hwang J-A, et al. Increased levels of plasma glial-derived neurotrophic factor in children with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015;69:546-51.
• Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48:209-25.
• Loe IM, Feldman HM. Academic and educational outcomes of children with ADHD. Journal of pediatric psychology. 2007;32(6):643-54.
• Volkow ND, Li T-K. Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther. 2005;108:3-17.
• de Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008;65:835-42.
• Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry 1997;36:1065-79.
• Tsai S-J. Attention-deficit hyperactivity disorder and brain-derived neurotrophic factor: a speculative hypothesis. Med Hypotheses. 2003;60:849-51.
• Rubia K. Neuro-anatomic evidence for the maturational delay hypothesis of ADHD. Proc Natl Acad Sci USA. 2007;104:19663-4.
• Liu D-Y, Shen X-M, Yuan F-F, Guo O-Y, Zhong Y, Chen J-G, et al. The physiology of BDNF and its relationship with ADHD. Mol Neurobiol. 2015;52:1467-76.
• Fumagalli F, Racagni G, Colombo E, Riva M. BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. Mol Psychiatry. 2003;8:898.
• Im Jeong H, Ji E-S, Kim S-H, Kim T-W, Baek S-B, Choi SW. Treadmill exercise improves spatial learning ability by enhancing brain-derived neurotrophic factor expression in the attention-deficit/hyperactivity disorder rats. J Exerc Rehabil. 2014;10:162.
• Li H, Liu L, Tang Y, Ji N, Yang L, Qian Q, et al. Sex-specific association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and plasma BDNF with attention-deficit/hyperactivity disorder in a drug-naïve Han Chinese sample. Psychiatry Res. 2014;217:191-7.
• Corominas-Roso M, Ramos-Quiroga JA, Ribases M, Sanchez-Mora C, Palomar G, Valero S, et al. Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2013;16:1267-75.
• Gadow KD, Roohi J, DeVincent CJ, Kirsch S, Hatchwell E. Association of COMT (Val158Met) and BDNF (Val66Met) gene polymorphisms with anxiety, ADHD and tics in children with autism spectrum disorder. J Autism Dev Disord. 2009;39:1542-51.
• Rios M, Fan G, Fekete C, Kelly J, Bates B, Kuehn R, et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol. 2001;15:1748-57.
• Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacol. 2002;27:699-711.
• Diamond A. Close interrelation of motor development and cognitive development and of the cerebellum and prefrontal cortex. Child Dev. 2000;71:44-56.
• Amico F, Stauber J, Koutsouleris N, Frodl T. Anterior cingulate cortex gray matter abnormalities in adults with attention deficit hyperactivity disorder: a voxel-based morphometry study. Psychiatry Res. 2011;191:31-5.
• Ouchi Y, Banno Y, Shimizu Y, Ando S, Hasegawa H, Adachi K, et al. Reduced adult hippocampal neurogenesis and working memory deficits in the Dgcr8-deficient mouse model of 22q11. 2 deletion-associated schizophrenia can be rescued by IGF2. J Neurosci. 2013;33:9408-19.
• Adisetiyo V, Tabesh A, Di Martino A, Falangola MF, Castellanos FX, Jensen JH, et al. Attention‐deficit/hyperactivity disorder without comorbidity is associated with distinct atypical patterns of cerebral microstructural development. Hum Brain Mapp. 2014;35:2148-62.
• Afshari FS, Chu AK, Sato‐Bigbee C. Effect of cyclic AMP on the expression of myelin basic protein species and myelin proteolipid protein in committed oligodendrocytes: differential involvement of the transcription factor CREB. J Neurosci Res. 2001;66:37-45.
• Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008;1211:37-43.
• Simchon-Tenenbaum Y, Weizman A, Rehavi M. Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration. Behav Brain Res. 2015;282:125-32.
• Amiri A, Parizi GT, Kousha M, Saadat F, Modabbernia M-J, Najafi K, et al. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit–hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:20-4.
• Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994;266(5187):1062-4.
• Bilgiç A, Toker A, Işık Ü, Kılınç İ. Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26:355-63.
• Clemow DB, Steers WD, Tuttle JB. Stretch‐activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J Cell Physiol. 2000;183:289-300.
• Guney E, Ceylan MF, Kara M, Tekin N, Goker Z, Dinc GS, et al. Serum nerve growth factor (NGF) levels in children with attention deficit/hyperactivity disorder (ADHD). Neurosci Lett. 2014;560:107-11.
• Syed Z, Dudbridge F, Kent L. An investigation of the neurotrophic factor genes GDNF, NGF, and NT3 in susceptibility to ADHD. Am J Med Genet B Neuropsychiatr Genet. 2007;144:375-8.
• Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA. 2002;99:11946-50.
• Jesmin S, Togashi H, Sakuma I, Mowa CN, Ueno K-I, Yamaguchi T, et al. Gonadal hormones and frontocortical expression of vascular endothelial growth factor in male stroke-prone, spontaneously hypertensive rats, a model for attention-deficit/hyperactivity disorder. Endocrinology. 2004;145:4330-43.
• Jesmin S, Togashi H, Mowa CN, Ueno K-i, Yamaguchi T, Shibayama A, et al. Characterization of regional cerebral blood flow and expression of angiogenic growth factors in the frontal cortex of juvenile male SHRSP and SHR. Brain Res. 2004;1030:172-82.
• Carmona S, Vilarroya O, Bielsa A, Tremols V, Soliva J, Rovira M, et al. Global and regional gray matter reductions in ADHD: a voxel-based morphometric study. Neurosci Lett. 2005;389:88-93.
• Rijlaarsdam J, Cecil CA, Walton E, Mesirow MS, Relton CL, Gaunt TR, et al. Prenatal unhealthy diet, insulin‐like growth factor 2 gene (igf2) methylation, and attention deficit hyperactivity disorder symptoms in youth with early‐onset conduct problems. J Child Psychol Psychiatry. 2017;58:19-27.
• Walton E, Pingault J-B, Cecil CA, Gaunt TR, Relton C, Mill J, et al. Epigenetic profiling of ADHD symptoms trajectories: a prospective, methylome-wide study. Molecular psychiatry. 2017;22(2):250.
• Smith KM, Fagel DM, Stevens HE, Rabenstein RL, Maragnoli ME, Ohkubo Y, et al. Deficiency in inhibitory cortical interneurons associates with hyperactivity in fibroblast growth factor receptor 1 mutant mice. Biol Psychiatry. 2008;63:953-62.
• Mooney MA, McWeeney SK, Faraone SV, Hinney A, Hebebrand J, Nigg JT, et al. Pathway analysis in attention deficit hyperactivity disorder: an ensemble approach. Am J Med Genet B Neuropsychiatr Genet 2016;171:815-26.
• Lauritsen MB. Autism spectrum disorders. Eur Child Adolesc Psychiatry. 2013;22:37-42.
• Howlin P. Autism spectrum disorders. Psychiatry. 2006;5:320-4.
• Mundy P, Kim K, McIntyre N, Lerro L, Jarrold W. Brief Report: Joint Attention and Information Processing in Children with Higher Functioning Autism Spectrum Disorders. J Autism Dev Disord. 2016:1-6.
• Demopoulos C, Hopkins J, Davis A. A comparison of social cognitive profiles in children with autism spectrum disorders and attention-deficit/hyperactivity disorder: a matter of quantitative but not qualitative difference? J Autism Dev Disord. 2013;43:1157-70.
• Ahmed FS, Miller LS. Executive function mechanisms of theory of mind. J Autism Dev Disord. 2011;41(5):667-78.
• Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47:921-9.
• Siu MT, Weksberg R. Epigenetics of autism spectrum disorders. Adv Exp Med Biol. 2017;978:63-90.
• Cohen OS, Varlinskaya EI, Wilson CA, Glatt SJ, Mooney SM. Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats. Int J Dev Neurosci. 2013;31:740-50.
• De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209.
• Meltzer A, Van de Water J. The role of the immune system in autism spectrum disorder. Neuropsychopharmacology. 2017;42:284.
• Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology. 2002;46:76-84.
• Casanova MF, van Kooten IA, Switala AE, van Engeland H, Heinsen H, Steinbusch HW, et al. Minicolumnar abnormalities in autism. Acta neuropathologica. 2006;112(3):287.
• Casanova MF, Buxhoeveden DP, Switala AE, Roy E. Minicolumnar pathology in autism. Neurology. 2002;58:428-32.
• Cerliani L, Mennes M, Thomas RM, Di Martino A, Thioux M, Keysers C. Increased functional connectivity between subcortical and cortical resting-state networks in autism spectrum disorder. JAMA Psychiatry. 2015;72:767-77.
• Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini L, et al. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. Cell. 2015;162:375-90.
• Russo AJ. Correlation between hepatocyte growth factor (HGF) and gamma-aminobutyric acid (GABA) plasma levels in autistic children. Biomark Insights. 2013;8:BMI:11448.
• Ha S, Sohn I-J, Kim N, Sim HJ, Cheon K-A. Characteristics of brains in autism spectrum disorder: structure, function and connectivity across the lifespan. Exp Neurobiol. 2015;24:273-84.
• Willsey AJ. Autism spectrum disorders: from genes to neurobiology. Curr Opin Neurobiol. 2015;30:92-9.
• Bonath B, Tegelbeckers J, Wilke M, Flechtner H-H, Krauel K. Regional gray matter volume differences between adolescents with ADHD and typically developing controls: further evidence for anterior cingulate involvement. J Atten Disord. 2016:1087054715619682.
• Casanova MF. The neuropathology of autism. Brain Pathol. 2007;17:422-33.
• van Kooten IA, Palmen SJ, von Cappeln P, Steinbusch HW, Korr H, Heinsen H, et al. Neurons in the fusiform gyrus are fewer and smaller in autism. Brain. 2008;131:987-99.
• Jacot-Descombes S, Uppal N, Wicinski B, Santos M, Schmeidler J, Giannakopoulos P, et al. Decreased pyramidal neuron size in Brodmann areas 44 and 45 in patients with autism. Acta Neuropathol. 2012;124:67-79.
• Abdallah MW, Mortensen EL, Greaves‐Lord K, Larsen N, Bonefeld‐Jørgensen EC, Nørgaard‐Pedersen B, et al. Neonatal levels of neurotrophic factors and risk of autism spectrum disorders. Acta Psychiatr Scand. 2013;128:61-9.
• Ashwood P, Enstrom A, Krakowiak P, Hertz-Picciotto I, Hansen RL, Croen LA, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol. 2008;204:149-53.
• Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2011;25:40-5.
• Depino AM, Lucchina L, Pitossi F. Early and adult hippocampal TGF-β1 overexpression have opposite effects on behavior. Brain Behav Immun. 2011;25:1582-91.
• Qin X-Y, Feng J-C, Cao C, Wu H-T, Loh YP, Cheng Y. Association of peripheral blood levels of brain-derived neurotrophic factor with autism spectrum disorder in children: a systematic review and meta-analysis. JAMA Pediatr. 2016;170:1079-86.
• Schuch V, Utsumi DA, Costa TVMM, Kulikowski LD, Muszkat M. Attention deficit hyperactivity disorder in the light of the epigenetic paradigm. Front Psychiatry. 2015;6:126.
• van Mil NH, Steegers-Theunissen RP, Bouwland-Both MI, Verbiest MM, Rijlaarsdam J, Hofman A, et al. DNA methylation profiles at birth and child ADHD symptoms. J Psychiatr Res. 2014;49:51-9.
• Lee IH, Seo EJ, Lim IS. Effects of aquatic exercise and CES treatment on the changes of cognitive function, BDNF, IGF-1, and VEGF of persons with intellectual disabilities. J Exerc Nutrition Biochem. 2014;18:19.
• Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2-16.
• Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry. 2002;7:673.
• Suzuki K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, et al. Decreased serum levels of epidermal growth factor in adult subjects with high-functioning autism. Biol Psychiatry. 2007;62:267-9.
• Russo AJ. Increased epidermal growth factor receptor (EGFR) associated with hepatocyte growth factor (HGF) and symptom severity in children with autism spectrum disorders (ASDs). J Cent Nerv Syst Dis. 2014;6:13767.
• Toyoda T, Nakamura K, Yamada K, Thanseem I, Anitha A, Suda S, et al. SNP analyses of growth factor genes EGF, TGFβ-1, and HGF reveal haplotypic association of EGF with autism. Biochem Biophys Res Commun. 2007;360:715-20.
• Russo AJ. Decreased epidermal growth factor (EGF) associated with HMGB1 and increased hyperactivity in children with autism. Biomark Insights. 2013;8:11270.
• Russo AJ. Decreased phosphorylated protein kinase B (Akt) in individuals with autism associated with high epidermal growth factor receptor (EGFR) and low gamma-aminobutyric acid (GABA). Biomark Insights. 2015;10:21946.
• Yang E-J, Ahn S, Lee K, Mahmood U, Kim H-S. Early behavioral abnormalities and perinatal alterations of PTEN/AKT pathway in valproic acid autism model mice. PloS One. 2016;11:0153298.
• Russo A, Krigsman A, Jepson B, Wakefield A. Decreased serum hepatocyte growth factor (HGF) in autistic children with severe gastrointestinal disease. Biomark Insights. 2009;4:3656.
• Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10:2867-78.
• Campbell DB, D'Oronzio R, Garbett K, Ebert PJ, Mirnics K, Levitt P, et al. Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann Neurol. 2007;62:243-50.
• Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA.;103:16834-9.
• Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001;49:597-606.
• Miyazaki K, Narita N, Sakuta R, Miyahara T, Naruse H, Okado N, et al. Serum neurotrophin concentrations in autism and mental retardation: a pilot study. Brain Dev. 2004;26:292-5.
• Correia C, Coutinho A, Sequeira A, Sousa I, Lourenco Venda L, Almeida J, et al. Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes Brain Behav. 2010;9:841-8.
• Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ, et al. Decreased serum levels of transforming growth factor-β1 in patients with autism. Progress in Neuro- Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:187-90.
• Bimonte-Nelson HA, Hunter CL, Nelson ME, Granholm A-CE. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav Brain Res. 2003;139:47-57.
• Tiveron C, Fasulo L, Capsoni S, Malerba F, Marinelli S, Paoletti F, et al. ProNGF\NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice. Cell Death Differ. 2013;20:1017.